Insulin and drugs that influence insulin secretion has been the cornerstone of pharmacological treatment of diabetes. Over the past 10 years, treatment of diabetes with incretins (both oral and injectable medications) has been added to correct a physiological abnormality present in people with diabetes that raises blood sugar. Research on animals reported in Cell Metabolism describes a new target for therapy. Glucagon, a hormone which protects the body against low blood sugar during fasting, is often secreted inappropriately in people with diabetes. While a drug that totally blocks glucagon has been shown to have bad effects, the new drug under development will block the harmful part of its effects and leave the beneficial part alone. This new drug has shown benefit in mice by lowering blood sugar, improving insulin resistance, and decreasing fatty deposits in the liver. In the meantime, live in hope and maintain good control. Let us know your feelings about this research. For the full article, click HERE.
MEDICAL ADVICE DISCLAIMER: The information included on this site is for educational purposes only. It is not intended nor implied to be a substitute for professional medical advice. The reader should always consult his or her health care provider to determine the appropriateness of the information for their own situation, or if they have any questions regarding a medical condition or treatment plan. Reading the information on this website does not create a physician-patient relationship.
